None listed
Conditions
Interventions
Intervention1: Reginald Men Hermes All In One Serum B No AHO250012: Participants will wash their hands properly before application of the product. Before every application the participant will wash th
Sponsors
BTM Ventures Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Healthy male & female participants in the age group of 18 45 years both age inclusive Participant is having valid proof of identity and age Participant is having apparently healthy skin on test area Participants must be of all skin types in almost equal proportion Normal Oily Combination Dry mild to moderate Facial acne and Moderate to severe facial acne sensitive No treatment for face in the past 1 month Participants willing to give voluntary written informed consent Participants willing to come for regular follow up visits Participants ready to follow instructions during the study period Participants without any open wounds cuts abrasions irritation symptoms on test area Participant willing to perform UPT for females only
Exclusion criteria
Exclusion criteria: Participants with Known hypersensitivity to any of the study products or constituents except for sensitive participants Participants with any kind of skin allergy antecedents or cutaneous disease or any significant pathology in the test area which may influence the study results Participants having topical or systemic treatment in last month prior to participation in the study and during the study that could interfere with the study treatments/ assessments Participant is Pregnant or Lactating Participant with any significant medical condition that would interfere with the participation in the trial Participants participated in any other cosmetic or therapeutic trial or in a similar investigation Participant is having Scars excessive terminal hair or tattoos on the test area
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comedogenicity of the test product Acne Control in terms of the assessment of IGA score lesion countTimepoint: Day 0 Day 7 Day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and Tolerability of the investigational product during the entire study duration of 28 DaysTimepoint: Day 0 Day 7 Day 28 | — |
Countries
India
Contacts
Public ContactDr Karishma Kapoor
Auriga Research Private Limited
Outcome results
None listed